Immune checkpoint inhibitors continue to revolutionize the treatment of a wide range of solid-tumor and hematological malignancies, with a growing list of approvals and label expansions. The Immune Checkpoint Inhibitors Special Topics report provides a comprehensive, multi-indication coverage of currently available immune checkpoint inhibitors — ipilimumab (Bristol Myers-Squibb’s Yervoy), nivolumab (Bristol Myers-Squibb’s Opdivo), pembrolizumab (Merck & Co.’s Keytruda), atezolizumab (Roche/Genentech’s Tecentriq), avelumab (Pfizer/Merck KGaA’s Bavencio), and durvalumab (AstraZeneca’s Imfinzi) — and examines their ongoing clinical development across oncology. In addition, analysis of late-phase emerging therapies and their future positioning is provided, along with an annualized top-down market forecast. The report also offers an extensive list of agents in early-phase development, as well as an analysis of the most promising novel targets and combination therapies for immune checkpoint inhibitors.

Questions Answered

  •  What is the landscape for current immune checkpoint inhibitors in oncology? What are the trends in their ongoing clinical development?
  • What are the key trends for emerging immune checkpoint inhibitors in late-phase development? How do interviewed experts perceive these therapies?
  • What is the market outlook for current and emerging immune checkpoint inhibitors across oncology?
  • What are the therapies and/or mechanisms of action to watch in the early-phase pipeline?
  • What is the potential of combinatorial approaches involving immune checkpoint inhibitors?

Related Reports

Biosimilars - Market Events And Forecast - Oncology

In 2019, sales of branded monoclonal antibody biologics in oncology exceeded $18 billion across the major markets (United States, EU5, and Jap...

View Details

Biomarkers In Oncology - Access & Reimbursement - Detailed, Expanded Analysis (US) Biomarkers In Oncology

Biomarkers have become an integral component of the treatment landscape for an increasing number of oncology indications. Patients’ biomarker status often directs prescription choice in malig...

View Details

Biosimilars - Geographic Focus: China - Biosimilars | China In-Depth | Oncology And Immunology | China

The approval of Shanghai Henlius Biotech's HLX01—a biosimilar of Roche's Rituxan (rituximab)—in February 2019 marked the beginning of the biosimilars era in China. Since then, b...

View Details

Biosimilars - Emerging Biosimilars - Special Topics: Oncology Biosimilars In The United States - Wave 2

Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the seco...

View Details